160 related articles for article (PubMed ID: 34379324)
1. Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety-Net Collaborative analysis.
Kronenfeld JP; Collier AL; Turgeon MK; Ju M; Alterio R; Wang A; Fernandez M; Porembka MR; Richter H; Lee AY; Russell MC; Merchant NB; Maker AV; Datta J
J Surg Oncol; 2021 Dec; 124(8):1317-1328. PubMed ID: 34379324
[TBL] [Abstract][Full Text] [Related]
2. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
[TBL] [Abstract][Full Text] [Related]
3. CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.
Tong Y; Zhao Y; Shan Z; Zhang J
BMC Cancer; 2021 Jan; 21(1):4. PubMed ID: 33402124
[TBL] [Abstract][Full Text] [Related]
4. Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands.
Brenkman HJF; Visser E; van Rossum PSN; Siesling S; van Hillegersberg R; Ruurda JP
Ann Surg Oncol; 2017 Jul; 24(7):1761-1769. PubMed ID: 28353020
[TBL] [Abstract][Full Text] [Related]
5. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
[TBL] [Abstract][Full Text] [Related]
6. Impact of anaemia in oesophago-gastric cancer patients undergoing curative treatment by means of neoadjuvant chemotherapy and surgery.
Chan BY; McKinlay S; Forshaw M; MacDonald A; Maitra R; Orizu M; McSorley ST
Surg Oncol; 2021 Sep; 38():101585. PubMed ID: 33930843
[TBL] [Abstract][Full Text] [Related]
7. Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer.
Ji X; Yang Q; Qin H; Zhou J; Liu W
J Int Med Res; 2019 Jun; 47(6):2524-2532. PubMed ID: 31039658
[TBL] [Abstract][Full Text] [Related]
8. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
9. Effects of Neoadjuvant Chemotherapy Toxicity and Postoperative Complications on Short-term and Long-term Outcomes After Curative Resection of Gastric Cancer.
Wu C; Wang N; Zhou H; Wang T; Mao Q; Zhang X; Zhao D
J Gastrointest Surg; 2020 Jun; 24(6):1278-1289. PubMed ID: 31140064
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy.
In H; Kantor O; Sharpe SM; Baker MS; Talamonti MS; Posner MC
Ann Surg Oncol; 2016 Jun; 23(6):1956-62. PubMed ID: 26753752
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy.
Vicente D; Ikoma N; Chiang YJ; Fournier K; Tzeng CD; Song S; Mansfield P; Ajani J; Badgwell BD
Ann Surg Oncol; 2018 Sep; 25(9):2720-2730. PubMed ID: 29987602
[TBL] [Abstract][Full Text] [Related]
12. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
14. Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma?
Gabriel E; Attwood K; Narayanan S; Brady M; Nurkin S; Hochwald S; Kukar M
J Surg Oncol; 2018 Mar; 117(4):659-670. PubMed ID: 29127704
[TBL] [Abstract][Full Text] [Related]
15. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
16. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
17. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.
Hayashi M; Fujita T; Matsushita H
Eur J Surg Oncol; 2021 Aug; 47(8):1996-2003. PubMed ID: 33353828
[TBL] [Abstract][Full Text] [Related]
19. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
20. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.
Fujitani K; Nakamura K; Mizusawa J; Kuwata T; Shimoda T; Katayama H; Kushima R; Taniguchi H; Yoshikawa T; Boku N; Terashima M; Fukuda H; Sano T; Sasako M;
Gastric Cancer; 2021 Jan; 24(1):197-204. PubMed ID: 32572792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
